MedTrace Logo

Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction

NCT02449070 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2017-09-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether nicorandil reduce cardiac infarct size in patient with ST-segment elevation acute myocardial infarction.

Conditions

Interventions

DRUG

Nicorandil

4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting

Sponsors & Collaborators

  • JW Pharmaceutical

    collaborator INDUSTRY

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • Jun-Hyok Oh, MD · Pusan National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2018-10-31
Completion
2018-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02449070 on ClinicalTrials.gov